GO:0014820 tonic smooth muscle contraction: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0014820 describes sustained, continuous force generation in tonic smooth muscle that lacks an ordered sarcomeric structure.
• Tonic contraction is driven by actin-myosin ATPase cycling and is tuned by Ca2+-dependent and Ca2+-sensitization pathways.
• The latch mechanism explains how tonic smooth muscle maintains force with low ATP consumption.
• Key regulators include MYH11, MYL9, MYL12B, ACTA2, and Ca2+/calmodulin-dependent kinases such as MYLK and PYK2.
• Dysregulated tonic contraction contributes to airway hyperresponsiveness, vascular tone abnormalities, and urethral dysfunction.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of tonic contraction genes.
Description
Tonic smooth muscle contraction (GO:0014820) is a biological process in which force is generated within tonic smooth muscle tissue, producing a sustained, continuous contraction without an ordered sarcomeric structure. Unlike phasic smooth muscle, which contracts and relaxes in discrete cycles, tonic smooth muscle maintains force over prolonged periods, a property essential for hollow organ function such as vascular tone, airway caliber, and urethral closure. The process relies on chemo-mechanical energy conversion by the actin/myosin complex, which generates force through ATP hydrolysis. Researchers study GO:0014820 to understand how sustained contractility is regulated at the molecular level and how its dysregulation contributes to disease. Key mechanisms include Ca2+-dependent activation of myosin light chain kinase (MYLK), phosphorylation of the 20-kDa myosin regulatory light chain (MYL9/MYL12B), and Ca2+-sensitization pathways that inhibit myosin light chain phosphatase. The latch hypothesis further explains how dephosphorylated cross-bridges maintain force at low energy cost. Because tonic contraction is central to airway, vascular, and urogenital physiology, it is a major target for therapeutic intervention and for CRISPR-based functional genomics.
tonic smooth muscle contraction At A Glance
| GO ID | GO:0014820 |
|---|---|
| GO term | tonic smooth muscle contraction |
| Ontology | biological_process |
| Synonym | none |
| Major function | Sustained force generation in tonic smooth muscle via actin/myosin ATP hydrolysis without ordered sarcomeres |
| Tissue context | Vascular, airway, urethral, and other tonic smooth muscle beds |
| Key regulatory event | Ca2+-dependent myosin light chain phosphorylation and Ca2+-sensitization |
| Energy strategy | Latch mechanism enables force maintenance at low ATP cost |
| Disease relevance | Airway hyperresponsiveness, vascular toxicity, urethral dysfunction |
What Is GO:0014820?
GO:0014820 (tonic smooth muscle contraction) is defined as a process in which force is generated within tonic smooth muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step carried out by the actin/myosin complex, which generates force through ATP hydrolysis. In tonic smooth muscle, contraction occurs without an ordered sarcomeric structure and manifests as a sustained continuous contraction.
Why Is tonic smooth muscle contraction Important in Cell Biology?
Tonic smooth muscle contraction is fundamental to the function of hollow organs, where sustained force maintains vascular tone, airway caliber, and urethral closure. Dysregulation of this process underlies major human diseases, including asthma, hypertension, and bladder outlet dysfunction. Understanding GO:0014820 at the molecular level is therefore essential for identifying therapeutic targets and for interpreting how genetic variants or drug exposures alter contractile behavior.
• Maintains vascular tone and blood pressure through sustained arterial smooth muscle contraction.
• Controls airway caliber; excessive tonic contraction contributes to asthma and airway hyperresponsiveness.
• Regulates urethral closure and continence; spontaneous activity in urethral smooth muscle is clinically relevant.
• Explains the latch phenomenon, allowing force maintenance with low ATP consumption.
• Provides a model for Ca2+-sensitization and kinase-dependent regulation of contractility.
• Is a target for drugs modulating smooth muscle tone in cardiovascular and respiratory disease.
• Doxorubicin-induced vascular toxicity impairs smooth muscle contraction, linking contractile biology to chemotherapy side effects.
• Serves as a functional readout for CRISPR screens of contractility genes.
What Happens During tonic smooth muscle contraction?
Calcium-dependent activation
In simple terms: Calcium enters the cell and switches on the contraction machinery.
In tonic smooth muscle, an increase in cytosolic Ca2+ activates calmodulin, which binds and activates myosin light chain kinase (MYLK). MYLK then phosphorylates the 20-kDa regulatory light chain of myosin (MYL9/MYL12B), enabling actin-activated myosin ATPase activity and cross-bridge cycling. This Ca2+-dependent step is the primary trigger for force generation in tonic smooth muscle.
Cross-bridge cycling and force generation
In simple terms: Myosin heads pull on actin filaments using ATP, generating force.
Phosphorylated myosin interacts with actin filaments, and ATP hydrolysis drives cross-bridge cycling that produces force and shortening. In tonic smooth muscle, the absence of an ordered sarcomeric structure means force is transmitted through a cytoskeletal network rather than regular sarcomeres. The chemo-mechanical energy conversion by the actin/myosin complex is the defining feature of GO:0014820.
Latch mechanism and sustained force
In simple terms: The muscle can hold force for a long time without using much energy.
The latch hypothesis proposes that dephosphorylated myosin cross-bridges remain attached to actin, maintaining force at low ATP consumption. This allows tonic smooth muscle to sustain continuous contraction efficiently, distinguishing it from phasic smooth muscle. The latch state is a hallmark of tonic contraction and is regulated by the balance of MYLK and myosin light chain phosphatase (MLCP) activities.
Ca2+-sensitization and kinase signaling
In simple terms: Other signals can make the muscle more sensitive to calcium, boosting contraction.
Ca2+-sensitization pathways inhibit MLCP, increasing phosphorylated myosin light chain at a given Ca2+ concentration. The Ca2+-dependent tyrosine kinase PYK2 (PTK2B) contributes to tonic depolarization-induced vascular smooth muscle contraction, illustrating kinase-dependent modulation. Molecular motors and their tuning also influence the contractile phenotype.
Energy metabolism and regulation
In simple terms: The muscle manages its energy use to keep contracting steadily.
Vascular smooth muscle energetics show that tonic contraction is supported by oxidative metabolism and efficient ATP use. Doxorubicin impairs smooth muscle cell contraction, demonstrating that metabolic or toxic stress can disrupt tonic contractility. These findings link GO:0014820 to cellular energy status and pharmacological exposure.
Key Genes Involved in GO:0014820 tonic smooth muscle contraction
The following genes and proteins are central to tonic smooth muscle contraction (GO:0014820) based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MYH11 | Smooth muscle myosin heavy chain; ATPase motor for force generation | Target for knockout to abolish contractility |
| MYL9 | 20-kDa regulatory myosin light chain; phosphorylation activates myosin | Point mutation of phosphorylation sites alters contraction |
| MYL12B | Regulatory myosin light chain isoform in smooth muscle | Knockout/knock-in to study isoform-specific function |
| ACTA2 | Smooth muscle alpha-actin; thin filament component | Knockout affects force transmission |
| MYLK | Myosin light chain kinase; Ca2+/calmodulin-dependent | Knockout reduces myosin phosphorylation and contraction |
| PPP1R12A | Myosin light chain phosphatase regulatory subunit; Ca2+-sensitization | Knockout increases contraction |
| PTK2B (PYK2) | Ca2+-dependent tyrosine kinase; tonic depolarization-induced contraction | Knockout/knockdown reduces tonic contraction |
| CALM1 | Calmodulin; Ca2+ sensor activating MYLK | Point mutation alters Ca2+ sensitivity |
| ROCK1 | Rho kinase; inhibits MLCP and promotes Ca2+-sensitization | Knockout reduces tonic force |
| ROCK2 | Rho kinase isoform; regulates smooth muscle tone | Knockout/overexpression studies |
| MYOCD | Myocardin; transcriptional coactivator of smooth muscle genes | Overexpression drives contractile phenotype |
| SRF | Serum response factor; regulates smooth muscle gene expression | Knockout impairs contractile gene program |
| LMOD1 | Leiomodin-1; actin filament regulator in smooth muscle | Knockout affects contractile apparatus |
| CNN1 | Calponin; actin-binding protein modulating contraction | Knockout alters contractility |
| ACTG2 | Smooth muscle gamma-actin; thin filament component | Point mutations linked to visceral myopathy |
| DES | Desmin; intermediate filament in smooth muscle | Knockout affects cytoskeletal integrity |
| VCL | Vinculin; focal adhesion protein in smooth muscle | Knockout alters force transmission |
| TLN1 | Talin-1; focal adhesion adaptor | Knockout affects contractile signaling |
How Is tonic smooth muscle contraction Regulated?
Tonic smooth muscle contraction is regulated by Ca2+-dependent activation of MYLK and by Ca2+-sensitization pathways that inhibit myosin light chain phosphatase, including RhoA/ROCK signaling. The Ca2+-dependent tyrosine kinase PYK2 contributes to tonic depolarization-induced contraction in vascular smooth muscle. Energy metabolism and oxidative phosphorylation also modulate sustained contraction. Pharmacological agents such as doxorubicin can impair contraction, indicating additional regulatory inputs.
tonic smooth muscle contraction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MYH11 | Asthma, vascular tone disorders | Knockout smooth muscle cells |
| PTK2B | Vascular dysfunction | Knockout/knockdown in vascular smooth muscle |
| MYLK | Airway hyperresponsiveness | Point mutation of phosphorylation sites |
| ROCK1 | Hypertension, asthma | Overexpression and knockout models |
| MYL9 | Smooth muscle contractility disorders | Phospho-mutant knock-in |
Airway hyperresponsiveness and asthma
Excessive tonic contraction of airway smooth muscle contributes to airway hyperresponsiveness in asthma. Regulation of airway smooth muscle contraction in health and disease involves Ca2+ signaling, kinase pathways, and inflammatory mediators. Targeting these pathways is a therapeutic strategy for bronchoconstriction.
Vascular dysfunction and drug-induced toxicity
Tonic contraction maintains vascular tone, and its dysregulation contributes to hypertension and vascular disease. Doxorubicin impairs smooth muscle cell contraction, providing insight into vascular toxicity of chemotherapy. PYK2-mediated signaling is implicated in tonic depolarization-induced vascular contraction.
Urethral dysfunction and continence disorders
Spontaneous activity in urethral smooth muscle influences continence, and altered tonic contraction can contribute to urinary dysfunction. Understanding the mechanisms of urethral smooth muscle activity is relevant to lower urinary tract symptoms.
From tonic smooth muscle contraction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of MYH11 abolish tonic contraction? | MYH11 knockout smooth muscle cells |
| Does PYK2 phosphorylation regulate tonic depolarization-induced contraction? | PTK2B point mutation (kinase-dead) knock-in |
| Does MYL9 phosphorylation site mutation alter force? | MYL9 phospho-mutant knock-in |
| Does overexpression of MYOCD drive contractile phenotype? | MYOCD overexpression in smooth muscle cells |
| Does ROCK inhibition reduce tonic force? | ROCK1/2 knockout or pharmacological inhibition |
| Does doxorubicin impair contraction via metabolic stress? | Doxorubicin-treated smooth muscle cells |
How to Study the tonic smooth muscle contraction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Muscle strip force measurement | Isometric force | Drug and genetic effects on tonic contraction |
| Gel contraction assay | Cell-mediated collagen contraction | Smooth muscle cell contractility |
| Phospho-Western blot | MYL9 phosphorylation | Kinase pathway activation |
| Ca2+ imaging | Intracellular Ca2+ dynamics | Ca2+ sensitivity and signaling |
| RNA-seq | Transcriptome changes | Contractile gene expression profiling |
| CRISPR knockout screening | Gene essentiality for contraction | Functional genomics of tonic contraction |
| Proteomics | Protein expression and modifications | Contractile apparatus composition |
| Immunofluorescence | Protein localization and cytoskeleton | Sarcomere-free organization |
Contractility assays
Force generation and shortening are measured using isolated smooth muscle strips or single-cell gel contraction assays. These assays directly quantify tonic contraction and are used to test genetic or pharmacological perturbations.
Phosphorylation and signaling analysis
Western blotting with phospho-specific antibodies detects MYL9 phosphorylation and kinase activation states. This is essential for linking molecular changes to contractile output.
Calcium imaging
Fluorescent Ca2+ indicators measure cytosolic Ca2+ transients and sustained Ca2+ levels in tonic smooth muscle. Ca2+ imaging helps distinguish Ca2+-dependent from Ca2+-sensitization mechanisms.
Genomic and transcriptomic profiling
RNA-seq and single-cell transcriptomics identify contractile gene programs and heterogeneity in smooth muscle populations. These methods support CRISPR screen validation and biomarker discovery.
How CRISPR Can Be Used to Study GO:0014820 tonic smooth muscle contraction
Knockout
CRISPR knockout of MYH11, MYLK, or PTK2B can abolish or reduce tonic contraction, providing causal evidence for gene function. Knockout models are used to validate hits from contractility screens.
Point Mutation
Point mutations in MYL9 phosphorylation sites or PTK2B kinase domain can dissect specific signaling events without altering protein levels. These models are valuable for structure-function studies of tonic contraction.
Knock-in
Knock-in of tagged or mutant alleles (e.g., phospho-mimetic MYL9) allows precise interrogation of contractile regulation. Knock-in reporters can track myosin light chain dynamics in live cells.
Overexpression
Overexpression of MYOCD or constitutively active ROCK can enhance the contractile phenotype and increase tonic force. Overexpression models help identify sufficiency of candidate regulators.
How EDITGENE Supports tonic smooth muscle contraction Research
Researchers studying tonic smooth muscle contraction-related genes often need to determine whether a candidate gene is causally involved in force generation, Ca2+-sensitization, or sustained contractility. EDITGENE provides CRISPR-based cell models and screening services to test these hypotheses rigorously.
Contact EDITGENE today to design your custom CRISPR model for tonic smooth muscle contraction research.
Frequently Asked Questions About tonic smooth muscle contraction
What is GO:0014820 tonic smooth muscle contraction?
GO:0014820 is a biological process describing sustained force generation in tonic smooth muscle without ordered sarcomeres, driven by actin/myosin ATP hydrolysis.
What genes are involved in tonic smooth muscle contraction?
Key genes include MYH11, MYL9, MYLK, PPP1R12A, PTK2B, ROCK1, and ACTA2, among others.
How does the latch mechanism work in tonic smooth muscle?
The latch mechanism maintains force through dephosphorylated myosin cross-bridges at low ATP cost, enabling sustained contraction.
What is the role of calcium in tonic smooth muscle contraction?
Calcium activates calmodulin and MYLK, leading to myosin light chain phosphorylation and cross-bridge cycling.
How is tonic smooth muscle contraction studied in the lab?
Methods include muscle strip force measurement, gel contraction assays, phospho-Western blotting, Ca2+ imaging, and CRISPR screens.
What diseases involve abnormal tonic smooth muscle contraction?
Asthma, hypertension, vascular toxicity, and urethral dysfunction are linked to dysregulated tonic contraction.
What is the difference between tonic and phasic smooth muscle contraction?
Tonic contraction is sustained and continuous without ordered sarcomeres, while phasic contraction occurs in discrete cycles.
Can CRISPR be used to study tonic smooth muscle contraction?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of contractility genes.
What is the role of PYK2 in tonic smooth muscle contraction?
PYK2 is a Ca2+-dependent tyrosine kinase that contributes to tonic depolarization-induced vascular smooth muscle contraction.
How does doxorubicin affect smooth muscle contraction?
Doxorubicin impairs smooth muscle cell contraction, providing insight into vascular toxicity.
Conclusion
GO:0014820 tonic smooth muscle contraction is a specialized biological process that sustains force in hollow organs through actin/myosin ATP hydrolysis and the latch mechanism. Its regulation by Ca2+-dependent kinases and Ca2+-sensitization pathways makes it a rich area for functional genomics. Dysregulation contributes to asthma, vascular disease, and urethral dysfunction, highlighting its clinical importance. CRISPR-based models from EDITGENE can accelerate the discovery of causal genes and therapeutic targets in tonic smooth muscle contraction.
References
- 1. Lam M et al.. 2019. Regulation of Airway Smooth Muscle Contraction in Health and Disease.. Adv Exp Med Biol 1124:381-422 PMID: 31183836
- 2. Mills RD et al.. 2015. A role for the Ca(2+)-dependent tyrosine kinase Pyk2 in tonic depolarization-induced vascular smooth muscle contraction.. J Muscle Res Cell Motil 36(6):479-89 PMID: 26150074
- 3. Horowitz A et al.. 1996. Mechanisms of smooth muscle contraction.. Physiol Rev 76(4):967-1003 PMID: 8874491
- 4. Marston SB. 1989. What is latch? New ideas about tonic contraction in smooth muscle.. J Muscle Res Cell Motil 10(2):97-100 PMID: 2668329
- 5. Sergeant GP et al.. 2019. Spontaneous Activity in Urethral Smooth Muscle.. Adv Exp Med Biol 1124:149-167 PMID: 31183826
- 6. Morano I. 2003. Tuning smooth muscle contraction by molecular motors.. J Mol Med (Berl) 81(8):481-7 PMID: 12879150
- 7. Paul RJ et al.. 1984. Vascular smooth muscle energetics.. J Cardiovasc Pharmacol 6 Suppl 2:S320-7 PMID: 6206340
- 8. Bosman M et al.. 2021. Doxorubicin Impairs Smooth Muscle Cell Contraction: Novel Insights in Vascular Toxicity.. Int J Mol Sci 22(23) PMID: 34884612
